Reddy’s and Mylan beat Vimovo
Two US method-of-treatment patents protecting Horizon Pharma’s Vimovo (naproxen/esomeprazole) delayed-release tablets up to 2031 are invalid on the ground of indefiniteness, Dr Reddy’s and Mylan have convinced New Jersey District Judge Stanley Chesler.
You may also be interested in...
Dr Reddy’s Laboratories has once again prevailed over Horizon Pharma and Nuvo in litigation over patents shielding the originators’ Vimovo, with the US Court of Appeals for the Federal Circuit affirming a lower court's invalidity ruling.
Dr Reddy’s has announced the launch of the first US generic version of Vimovo delayed-release tablets. However, Nuvo has warned that the at-risk launch infringes patents protecting the arthritis pain treatment until May 2022.
Three generics players in the US have helped to clear the path for generic rivals to the Vimovo analgesic by winning an appeals verdict of written descriptions for two patents.